DAJY(SZ:002030)2022-03-30 16:00Financial Performance - The company's operating revenue for 2021 reached ¥7,664,262,202.27, representing a 43.49% increase compared to ¥5,341,209,627.83 in 2020 [28]. - Net profit attributable to shareholders for 2021 was ¥3,618,186,564.12, a 47.74% increase from ¥2,449,090,154.35 in 2020 [28]. - The net profit after deducting non-recurring gains and losses was ¥3,537,112,727.59, up 49.41% from ¥2,367,365,192.11 in 2020 [28]. - The net cash flow from operating activities for 2021 was ¥3,304,545,784.75, an increase of 31.42% compared to ¥2,514,511,529.56 in 2020 [28]. - Basic earnings per share for 2021 were ¥2.5781, reflecting a 47.73% increase from ¥1.7451 in 2020 [28]. - Total assets at the end of 2021 amounted to ¥10,336,444,131.31, a 54.27% increase from ¥6,700,027,768.66 at the end of 2020 [28]. - Net assets attributable to shareholders reached ¥7,351,336,362.39, up 72.22% from ¥4,268,624,949.35 at the end of 2020 [28]. - The total profit reached ¥4,120,081,464.63, marking a 41.93% increase year-over-year, while the net profit attributable to shareholders was ¥3,618,186,564.12, up by 47.74% [61]. - The company reported a net income of ¥81,073,836.53, demonstrating stable financial performance amidst market fluctuations [37]. Market and Industry Trends - The IVD market is expected to grow at a rate of over 5% globally, driven by advancements in diagnostic technology and increased health awareness [42]. - The domestic IVD market is projected to grow at approximately 15%, fueled by the ongoing medical reform and the impact of the COVID-19 pandemic [43]. - The overall industry is experiencing a trend towards consolidation, with an increasing concentration of traditional diagnostic technology platforms [43]. - The company anticipates that the demand for personalized testing in areas such as oncology and genetic diseases will create substantial growth opportunities in molecular diagnostics [45]. Research and Development - The company focuses on the research and development of clinical diagnostic technologies and products, aiming to become a top-tier supplier in the in vitro diagnostics industry [48]. - The company has developed a comprehensive product line that addresses infectious diseases, prenatal care, precision medicine, and public health, among others [48]. - The company has made significant advancements in high-sensitivity detection systems for diseases, including a new integrated detection system for hepatitis C [96]. - The company achieved a significant increase in R&D investment, totaling approximately ¥631.77 million in 2021, up 166.32% from ¥237.22 million in 2020 [99]. - R&D expenditure accounted for 8.24% of total revenue in 2021, compared to 4.44% in 2020, reflecting a 3.80% increase [99]. - The number of R&D personnel rose to 790 in 2021, a 156.49% increase from 308 in 2020, although their proportion of total employees decreased by 4.03% [98]. Product Development and Offerings - The product portfolio includes a wide range of diagnostic kits, such as the 2019-nCoV nucleic acid test kits and various hepatitis virus detection kits, covering multiple disease areas [49]. - The company has developed a series of diagnostic reagents for acute infectious diseases, aiming to enhance market competitiveness and diagnostic efficiency [95]. - New product launches included a series of advanced diagnostic kits, contributing to a 30% increase in product sales [180]. - The company plans to enhance its R&D capabilities by building a "wall-less" research institute and accelerating the development of integrated product lines including core raw materials, diagnostic reagents, consumables, and specialized equipment [125]. Strategic Focus and Expansion - The strategic focus on expanding into new markets and enhancing product offerings is expected to drive future revenue growth [42]. - The company is focused on expanding its market presence and exploring potential mergers and acquisitions to strengthen its competitive edge [48]. - The company plans to enhance its market presence in Southeast Asia, targeting a 10% market share by 2023 [172]. - A strategic acquisition of a biotechnology firm is in progress, aimed at enhancing research capabilities and product offerings [172]. - The company is exploring potential mergers and acquisitions to strengthen its market position, with a budget of 500 million RMB allocated for this purpose [180]. Corporate Governance and Management - The company emphasizes the importance of maintaining a robust governance structure in compliance with relevant laws and regulations [145]. - The company has established a comprehensive investor relations management section on its website to ensure transparent information disclosure and communication with investors [152]. - The company has a complete and independent financial accounting system, with separate financial departments and bank accounts from its controlling shareholder [160]. - The company has a diverse board with members holding various positions in other companies, indicating a broad network [186]. - The company has implemented a structured decision-making process for determining executive compensation [187]. Social Responsibility and Community Engagement - The company actively participated in social responsibility initiatives, providing technical support for nucleic acid testing and donating a total of ¥1,000,000 to various charitable causes throughout the year [71]. - The company donated a total of RMB 3,000,000 to various educational and healthcare initiatives in 2021 [72][73][74]. - The company purchased poverty alleviation products worth RMB 443,190 to support local farmers [73]. Future Outlook and Guidance - The company has outlined performance guidance for the next fiscal year, expecting continued growth [169]. - The company plans to enhance its product market coverage and sales scale while maintaining good product profitability [134]. - The company reported a revenue guidance for 2022, projecting a growth rate of 25% year-on-year, aiming for 1.875 billion RMB [182].